Bimatoprost ophthalmic solution in facial vitiligo

Jha, Abhijeet Kumar; Prasad, Smita; Sinha, Rajesh

doi:10.1111/jocd.12443

Cited by 19 publications

(16 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…18 Another study by Jha et al assessed the efficacy of 0.03% bimatoprost in treating stable facial vitiligo lesions. 10 This showed that half of the patients had more than 50% repigmentation by week 12. The results of this study supported the idea that the treatment on facial lesions offered the best response.…”

Section: P Valuementioning

confidence: 95%

“…Previous clinical study by Grim et al was conducted in nonfacial vitiligo using 0.03% of bimatoprost solution, and no patients achieved greater than 50% repigmentation 18. Another study by Jha et al assessed the efficacy of 0.03% bimatoprost in treating stable facial vitiligo lesions 10. This showed that half of the patients had more than 50% repigmentation by week 12.…”

mentioning

confidence: 99%

“…[6][7][8][9] Previous reports have suggested a successful outcome with topical bimatoprost as treatment for facial vitiligo. 10 However, a study comparing the efficacy and safety between bimatoprost and conventional treatment of vitiligo has never been conducted. The objective of this study is to evaluate the treatment efficacy of 0.01% bimatoprost solution, compared to topical 0.1% tacrolimus ointment in nonsegmental facial vitiligo.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Clinical outcomes of topical bimatoprost for nonsegmental facial vitiligo: A preliminary study

Kanokrungsee

Pruettivorawongse

Rajatanavin

2020

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Vitiligo is a common acquired pigmentary disorder characterized by circumscribed white patches of depigmentation on the skin. It is caused by the destruction of melanocytes in certain areas. The prevalence of vitiligo is approximately 0.5-1% of worldwide population. 1 All races are affected, and the prevalence of vitiligo between male and female do not differ. It may appear at any age, but it presents earlier among females, and more than half of them present with symptoms of vitiligo before the age of 20. 2 Vitiligo is a multifactorial disease with complex pathogenesis, and both genetic and environmental factors play an important role

show abstract

Section: P Valuementioning

confidence: 95%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Clinical outcomes of topical bimatoprost for nonsegmental facial vitiligo: A preliminary study

Kanokrungsee

Pruettivorawongse

Rajatanavin

2020

J of Cosmetic Dermatology

View full text Add to dashboard Cite

show abstract

“…The observation of iris and periocular skin hyperpigmentation in patients with glaucoma led to its use in vitiligo (55). This hyperpigmentation seems to be due to an increase in melanogenesis (56).…”

Section: Methotrexate (Mtx)mentioning

confidence: 99%

Updates and new medical treatments for vitiligo (Review)

et al. 2021

View full text Add to dashboard Cite

Vitiligo is a multifactorial disease characterized by the loss of skin pigment, which results in achromic macules and patches. There are currently several medical treatments available, which aim to arrest progression and induce skin repigmentation. These treatments alone or combined have exhibited varying degrees of pigmentation, and the majority are safe and effective. All therapies for vitiligo are limited, and no known treatment can consistently produce repigmentation in all patients. Individualized treatment is appropriate according to the location, clinical presentation and the presence of disease activity. The present review summarizes the medical treatments available for vitiligo: Systemic and topic pharmacological therapies, physical and depigmentation treatments. Several treatments are still underway and have not yet been approved. However, due to the promising preliminary results, these are also mentioned in the present review. Contents 1. Introduction 2. Pharmacological treatment 3. Physical therapy 4. Depigmentation therapies 5. Conclusions

show abstract

“…Indeed, this analysis, correlated with other parameters such as onset age and associated diseases, may help the researchers to define and categorize the different variants of vitiligo, since a rigorous clinical classification is still missing [ 3 , 4 , 5 ]. Also, the patches detection and area measurement can help assessing the treatment effectiveness [ 6 , 7 ]. To this purpose, recent studies demonstrated that black light (around 365 nm [ 8 ]) is crucial in highlighting vitiligo patches, enhancing the contrast with respect to healthy skin [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

Semi-Automatic Tool for Vitiligo Detection and Analysis

Neri

Fiaschi²,

Menchini³

2020

J. Imaging

View full text Add to dashboard Cite

Vitiligo vulgaris is an autoimmune disease which causes a strong reduction of the cells producing melanin, which is the main skin pigment. This results in the growth of white patches on patients’ skin, which are more or less visible, depending on the skin phototype. Precise, objective and fast detection of vitiligo patches would be crucial to produce statistically relevant data on huge populations, thus giving an insight on the disease. However, few methods are available in literature. In the present paper, a semi-automatic tool based on image processing to detect facial vitiligo patches is described. The tool requires pictures to be captured under black light illumination, which enhances patches contrast with respect to healthy skin. The user is only required to roughly define the regions of interest and set a global threshold, thus, no specific image-processing skills are required. An adaptive algorithm then automatically discerns between vitiligo and healthy skin pixels. The tools also allow for a statistical data interpretation by overlapping the detected patches of all patients on a face template through an occurrence map. Preliminary results obtained on a small population of 15 patients allowed us to assess the tool’s performance. Patch detection was checked by an experienced dermatologist, who confirmed the detection for all the studied patients, thus supporting the effectiveness of the proposed tool.

show abstract

Bimatoprost ophthalmic solution in facial vitiligo

Abstract: Bimatoprost seems to be promising in treating stable vitiligo but large-scale studies are required.

Cited by 19 publications

References 10 publications

Clinical outcomes of topical bimatoprost for nonsegmental facial vitiligo: A preliminary study

Clinical outcomes of topical bimatoprost for nonsegmental facial vitiligo: A preliminary study

Updates and new medical treatments for vitiligo (Review)

Semi-Automatic Tool for Vitiligo Detection and Analysis

Contact Info

Product

Resources

About